XenoTherapeutics on Wednesday named its first chief medical officer, Michael Yaremchuk.
Boston-based XenoTherapeutics is working to advance what’s known as xenotransplantation, or the process of grafting or transplanting organs or tissues between members of different species. Its first product to enter the clinic, Xeno-Skin, is genetically engineered pig skin intended to temporarily close human burn wounds.
Yaremchuk is director of craniofacial surgery at Massachusetts General Hospital, where XenoTherapeutics is currently conducting a Phase I clinical trial of Xeno-Skin.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
